Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-04-26
2005-04-26
Henley, III, Raymond J (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S397000, C514S399000
Reexamination Certificate
active
06884809
ABSTRACT:
The invention provides a method for reducing cardiac dysfunctions in a human. The method comprises administration to the human of an effective amount of a selective histamine H3Receptor agonist. In one embodiment, the method comprises limiting the accumulation of intracellular sodium (Nai) by inhibiting the Na+/H+exchanger activity in the human having a cardiac dysfunction, or a predisposition to a cardiac dysfunction. In another embodiment the method comprises inhibiting the N-type Ca2+channel to modulate the concentration of intracellular calcium. The invention also provides a pharmaceutical composition that includes a selective histamine H3Receptor agonist with a pharmaceutical carrier.
REFERENCES:
patent: 5821259 (1998-10-01), Theoharides
patent: 5908853 (1999-06-01), Nahoum
patent: 6136559 (2000-10-01), Lovenberg et al.
patent: 6159994 (2000-12-01), McDonald et al.
patent: WO00/20011 (2000-04-01), None
Avery's Drug Treatment, 3rdedition (1987), pp. 611 and 614-621.*
Database CAPLUS on STN, (Columbus, OH, USA), No. 122:78176, Unmasking of activated H3-receptors in myocardial ischemia: their role as regulators of exocytotic norepinepherine release,J. Pharmacology. Exp. Ther., Imamura et al., 1994, 27(3):1259-1266 (abstract only).
Database CAPLUS on STN, (Columbus, OH, USA), No. 117:226854, Inhibition of sympathetic hypertensive response in the guinea pig by prejunctional histamine H3-receptors,Br. J. Pharmacol., Hey et al., 1992, 107(2):347-351 (abstract only).
Database CAPLUS on STN, (Columbus, OH, USA), No. 123:48330, Functional identification of histamine H3-receptors in the human heart. Circ. Res., Imamura et al., 1995, 77(1):206-210 (abstract only).
Hatta et al., “Activation of Histamine H3Receptors Inhibits Carrier-Mediated Norepinephrine Release in a Human Model of Protracted Myocardial Ischemia”,The Journal of Pharmacology and Experimental Therapeutics1997, 283(2):494-500.
Mackins et al., “Therapeutic potential of H3-receptor agonists in myocardial infarction”,Exp. Opin. Invest. Drugs2000, 9(11):1-6.
Karmazyn et al., “The Myocardial Na+-H+Exchange Structure, Regulation, and Its Role in Heart Disease”,Circulation Research1999, 85:777-786.
Kockskämper et al., “Activated of the cAMP-protein kinase A pathway facilitates Na+translocation by the Na+-K+pump in guinea-pig ventricular myocytes”,Journal of Physiology2000, 523.3:561-574.
Leurs et al., “Therapeutic potential of histamine H3receptor agonists and antagonists”,TiPS1998, 19:177-183.
Mazenot et al., “In vivo demonstration of H3-histaminergic inhibition of cardiac sympathetic stimulation by R-α-methyl-histamine and it prodrug BP 2.94 in the dog”,British Journal of Pharmacology1999, 126:264-268.
Rupprecht et al., “Cardioprotective Effects of the Na+/H+Exchange Inhibitor Cariporide in Patients with Acute Anterior Myocardial Infarction Undergoing Direct PTCA”,Circulation2000, 101:2902-2908.
Silver et al., “Coupling of histamine H3receptors to neuronal Na+/H+exchange: A novel protective mechanism in myocardial ischemia”,PNAS2001, 98(5):2855-2859.
Theroux, “Myocardial Cell Protection A Challenging Time for Action and a Challenging Time of Clinical Research”,Circulation2000, 101:2874-2876.
Wellman et al., “ATP-sensitive K+channel activation by calcitonin gene-related peptide and protein kinase A in pig coronary arterial smooth muscle”,Journal of Physiology1998, 507.1:117-129.
B Malinowska, et al., “Histamine H3Receptors—General Characterization and Their Function in the Cardiovascular System”,Journal of Physiology and Pharmacology, 1998. 49(2):191-211.
H. van der Goot, et al., “Isothiourea Analogues of Histamine as Potent Agonists or Antagonists of the Histamine H3-Receptor”Eur. J. Med. Chem. 1992. 27: 511-517.
Iwan J.P. De Esch, et al., “Characterization of the Binding Site of the Histamine H3Receptor. 1. Various Approaches to the Synthesis of 2-(1H-Imidazol-4-yl) cyclopropylamine and Histaminergic Activity of (1R,2R)- and (1S,2S)-2-(1H-Imidazol-4-yl)-cyclopropylamine”,Journal of Medicinal Chemistry, 1999. 42(7): 1115-1122.
Christina J. Mackins, et al., “Therapeutic Potential of H3-receptor Agonists in Myocardial Infarction”,Exp. Opin. Invest Drugs2000. 9(11): 2537-2542.
Catherine Mazenot, et al., “Histamine H3-receptor Stimulation is Unable to Modulate Noradrenaline Release by the Isolated Rat Heart During Ischaemia-Reperfusion”,Fundam. Clin. Pharmacol. 1999. 13(4): 455-60.
Catherine Mazenot, et al., “In vivo Demonstration of H3-histaminergic Inhibition of Cardiac Sympathetic Stimulation by R-α-methyl-histamine and its Prodrug BP 2.94 in the Dog”,British Journal of Pharmacology1999. 126: 264-268.
Pierre Theroux, M.D., “Myocardial Cell Protection. A Challenging Time for Action and Challenging Time of Clinical Research”,Circulation2000.
Hans-Jurgen Rupprecht, M.D., et al., “Cardioprotective Effects of the Na+/H+Exchange Inhibitor Cariporide in Patients with Acute Anterior Myocardial Infarction Undergoing Direct PTCA”,Circulation2000. 101:2902-2908.
Morris Karmazyn, et al., “The Myocardial Na+-H+Exchange. Structure, Regulation and Its Role in Heart Disease”,Circulation Research1999. 85:777-786.
Eiichiro Hatta, et al., “Activation of Histamine H3Receptors Inhibits Carrier-Mediated Norepinephrine Release in a Human Model of Protracted Myocardial Ischemia”,Journal of Pharmacology and Experimental Therapeutics1997. 283:494-500.
Randi B. Silver, et al., “Coupling of Histamine H3Receptors to Neuronal Na+/H+Exchange: A Protective Mechanism in Myocardial Ischemia”,PNAS Early Edition2001. 1-5.
Rob Leurs, et al., “Therapeutic Potential of Histamine H3Receptor Agonists and Antagonists”,Trends in Pharmacological Sciences1998. 19:177-183.
P.K. Rangachari, “The Fate of Released Histamine: Reception, Response and Termination”,Yale Journal of Biology and Medicine1998. 71:173-182.
Randi B. Silver, et al., “Coupling of Histamine H3receptors to Neuronal Na+/H+Exchange: A Novel Protective Mechanism in Myocardial Ischemia”,PNAS2001. 98(5):2855-2859.
Michiaki Imamura, et al., “Activation of Histamine H3-Receptors Inhibits Carrier-Mediated Norepinephrine Release During Protracted Myocardial Ischemia”,Circ. Res. 1996. 78:475-481.
Roberto Levi, et al., “Histamine H3-Receptors: A New Frontier in Myocardial Ischemia”,The Journal of Pharmacology and Experimental Therapeutics2000. 292:825-830.
H.D. Holtje, et al., “Molecular Modelling Studies on Histamine H2- and H3- Receptor Agonists”, www.pharm.uni-duesseldorf.de/forschung/mitabeiter/sippl/Maastricht.pdf. 1-12 No date available.
Patrizio Blandina, “The Role of Interactions Between Histaminergic and Cholinergic Systems in Learning and Memory”, www.mcmaster.ca/inabis98/huston/blandina0227/two.html (No date available).
Rob Leurs, et al., “Histamine Receptors”,Tocris cookson. www.biotrend.com/pdf/histamine.pdf. 1-6 (no date available).
Akagi, et al., “Role of histamine H3receptor on hypoxia-reoxygenation-induced cardiac dysfunction in guinea pigs”, PubMed No. 8750792,Methods Find Exp. Clin. Pharmacol., 1995, vol. 17 Suppl C:30-35. (abstract only).
Imamura, Michiaki, et al., “Histamine H3-Receptor-Mediated Inhibition of Calcitonin Gene-Related Peptide Release From Cardiac C Fibers”,Circulation Research1996, 78(5):863-869.
Luo, Xiao-Xing, et al., “Histamine H3-receptors inhibit sympathetic neurotransmission in guinea pig myocardium”,European Journal of Pharmacology1991, 204:311-314.
Levi Roberto
Silver Randi B.
Cornell Research Foundation Inc.
Feit Irving N.
Henley, III Raymond J
Hoffmann & Baron , LLP
LandOfFree
Method and compositions for reducing cardiac dysfunctions... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method and compositions for reducing cardiac dysfunctions..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method and compositions for reducing cardiac dysfunctions... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3420591